Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2016, Article ID 9639585, 7 pages
http://dx.doi.org/10.1155/2016/9639585
Case Report

Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine

1Department of Immunology, Oslo University Hospital, Montebello, 0310 Oslo, Norway
2Department of Clinical Cancer Research, Oslo University Hospital, Montebello, 0310 Oslo, Norway
3Department of Cell Therapy, Oslo University Hospital, Montebello, 0310 Oslo, Norway

Received 11 March 2016; Accepted 13 June 2016

Academic Editor: Jens Sondergaard

Copyright © 2016 Mouldy Sioud et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [10 citations]

The following is the list of published articles that have cited the current article.

  • Hector Rodriguez Cetina Biefer, Anju Vasudevan, and Abdallah Elkhal, “Aspects of Tryptophan and Nicotinamide Adenine Dinucleotide in Immunity: A New Twist in an Old Tale,” International Journal of Tryptophan Research, vol. 10, pp. 117864691771349, 2017. View at Publisher · View at Google Scholar
  • Kristian M. Hargadon, “Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma,” Frontiers in Immunology, vol. 8, 2017. View at Publisher · View at Google Scholar
  • Chahal Kailashiya, Jyotsna Kailashiya, and Hanjabam Barun Sharma, “Telomerase based anticancer immunotherapy and vaccines approaches,” Vaccine, vol. 35, no. 43, pp. 5768–5775, 2017. View at Publisher · View at Google Scholar
  • Diana A Steppan, Christine A Pratilas, and David M Loeb, “Targeted therapy for soft tissue sarcomas in adolescents and young adults.,” Adolescent health, medicine and therapeutics, vol. 8, pp. 41–55, 2017. View at Publisher · View at Google Scholar
  • Remy Thomas, Ghaneya Al-Khadairi, Jessica Roelands, Wouter Hendrickx, Said Dermime, Davide Bedognetti, and Julie Decock, “NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives,” Frontiers in Immunology, vol. 9, 2018. View at Publisher · View at Google Scholar
  • Mouldy Sioud, “T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors,” Scandinavian Journal of Immunology, vol. 87, no. 3, pp. e12643, 2018. View at Publisher · View at Google Scholar
  • Bartosz Szostak, Filip Machaj, Jakub Rosik, and Andrzej Pawlik, “CTLA4 antagonists in phase I and phase II clinical trials, current status  and  future perspectives for cancer therapy,” Expert Opinion on Investigational Drugs, pp. 1–11, 2018. View at Publisher · View at Google Scholar
  • Eishiro Mizukoshi, and Shuichi Kaneko, “Telomerase-Targeted Cancer Immunotherapy,” International Journal of Molecular Sciences, vol. 20, no. 8, pp. 1823, 2019. View at Publisher · View at Google Scholar
  • Mouldy Sioud, “Releasing the Immune System Brakes Using siRNAs Enhances Cancer Immunotherapy,” Cancers, vol. 11, no. 2, pp. 176, 2019. View at Publisher · View at Google Scholar
  • Yao-Hua Liu, I-Jeng Yeh, Ming-Derg Lai, Kuan-Ting Liu, Po-Lin Kuo, and Meng-Chi Yen, “Cancer Immunotherapy: Silencing Intracellular Negative Immune Regulators of Dendritic Cells,” Cancers, vol. 11, no. 1, pp. 108, 2019. View at Publisher · View at Google Scholar